Ashland Inc.
ashland.comWhat Do They Do?
Sells specialty ingredients for medicines and nutrition, personal and household care products, and industrial uses such as paints, construction materials, and chemicals.
10-K for FY2025, filed Nov 20, 2025Life Sciences is comprised of pharmaceuticals, nutrition, agricultural chemicals, diagnostic films (formerly known as advanced materials)…View ↗
Personal Care is comprised of biofunctionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and…View ↗
Specialty Additives is comprised of rheology and performance-enhancing additives serving the architectural coatings, construction, energy…View ↗
Intermediates is comprised of the production of 1,4 butanediol ("BDO") and related derivatives, including n-methylpyrrolidone. These…View ↗
How Do They Make Money?
Customers pay for goods under contracts or purchase orders, usually when products ship or are delivered. Ashland generally collects payment within 60 days of delivery.
10-K for FY2025, filed Nov 20, 2025Ashland’s sales are measured as the amount of consideration it expects to receive in exchange for transferring goods and are recognized…View ↗
A performance obligation is deemed to be satisfied by Ashland when control of the product or service is transferred to the customer. The…View ↗
All of Ashland’s sales are derived from contracts or purchase orders with customers, and nearly all contracts or purchase orders with…View ↗
-
10-K for FY2025, filed Nov 20, 2025
FY2025 revenue by reportable segment ↗
$1.8B
-
10-K for FY2025, filed Nov 20, 2025
$1.8B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Life Sciences
Sold outright
10-K for FY2025, filed Nov 20, 2025 |
35%
FY2022: 34%
|
Life Sciences, FY2025
$641M Sources
|
Sold outright |
|
Personal Care
Sold outright
10-K for FY2025, filed Nov 20, 2025 |
32%
FY2022: 28%
|
Personal Care, FY2025
$577M Sources
|
Sold outright |
|
Specialty Additives
Sold outright
10-K for FY2025, filed Nov 20, 2025 |
28%
FY2022: 30%
|
Specialty Additives, FY2025
$511M Sources
|
Sold outright |
|
Intermediates
Sold outright
|
7.5%
FY2022: 11%
|
Intermediates, FY2025
$137M Sources
|
Sold outright |
Who Are Their Customers?
Pharmaceutical, food and beverage manufacturers, and hospitals and radiologists buy Life Sciences products; consumer-product formulators buy personal-care ingredients, while industrial manufacturers buy additives and chemical intermediates.
10-K for FY2025, filed Nov 20, 2025Life Sciences is comprised of pharmaceuticals, nutrition, agricultural chemicals, diagnostic films (formerly known as advanced materials)…View ↗
Personal Care is comprised of biofunctionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and…View ↗
Specialty Additives is comprised of rheology and performance-enhancing additives serving the architectural coatings, construction, energy…View ↗
Key customers include Ashland’s Life Sciences, Personal Care and Specialty Additives segments, general industrial manufacturers, plastics…View ↗
Do Revenues Turn Into Profits?
No. It lost $845M in FY2025.
10-K for FY2025, filed Nov 20, 2025
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Jul 29, 2026
$16MView ↗
- ▲ Now profitable
- vs −$742M in Q3 FY2025
10-Q for Q3 FY2026, filed Jul 29, 2026
Open tableView ↗
-
Jul 28, 2026
Ashland appointed two directors and formed a capital allocation committee
The appointments and committee followed a cooperation agreement with stockholder Ancora.
Sources
8-K, filed Jul 28, 2026
On July 27, 2026, the Board of Directors (the “Board”) of Ashland Inc. (the “Company”) appointed Peter Thomas and Allen Spizzo (each a “New…View ↗
-
Jul 28, 2026
Ashland reaffirmed its fiscal 2026 sales and adjusted EBITDA outlook
The company reaffirmed its full-year sales and adjusted EBITDA guidance.
Sources
8-K, filed Jul 28, 2026
Ashland reports third quarter 2026 results and reaffirms full-year sales & Adjusted EBITDA outlookView ↗
-
Apr 28, 2026
Ashland lowered its fiscal 2026 adjusted EBITDA outlook
The updated outlook reflected slower productivity at Hopewell and variable demand in some areas.
Sources
8-K, filed Apr 28, 2026
Ashland reports second quarter fiscal 2026 results and updates full-year outlookView ↗
Shrinking. Revenue fell 14% in 4 years, from $2.1B in FY2021 to $1.8B in FY2025, about 4% a year.
Portfolio changes
Life Sciences no longer includes nutraceuticals, after the company sold that business. Its current description covers pharmaceuticals, nutrition, agricultural chemicals, diagnostic films and fine chemicals.
10-K for FY2022, filed Nov 21, 2022 10-K for FY2025, filed Nov 20, 2025Life Sciences is comprised of pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, diagnostic films (formerly known as…View ↗
Life Sciences is comprised of pharmaceuticals, nutrition, agricultural chemicals, diagnostic films (formerly known as advanced materials)…View ↗
Loading...
